Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CALC Stock Forecast 2026-2027
$5.47
Current Price
$78.82M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CALC Price Targets
+265.6%
To High Target of $20.00
+183.4%
To Median Target of $15.50
+155.9%
To Low Target of $14.00
CALC Price Momentum
+2.6%
1 Week Change
+18.1%
1 Month Change
+81.1%
1 Year Change
-17.0%
Year-to-Date Change
-24.0%
From 52W High of $7.20
+285.2%
From 52W Low of $1.42
📊 TOP ANALYST CALLS
Did CALC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Calcimedica is one of their latest high-conviction picks.
Latest CALC Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, CALC has a bullish consensus with a median price target of $15.50 (ranging from $14.00 to $20.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $5.47, the median forecast implies a 183.4% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 265.6% upside. Conversely, the most conservative target is provided by Leland Gershell at Oppenheimer, suggesting a 155.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CALC Analyst Ratings
4
Buy
0
Hold
0
Sell
CALC Price Target Range
Low
$14.00
Average
$15.50
High
$20.00
Current: $5.47
Latest CALC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CALC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Apr 1, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Mar 4, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Dec 17, 2024 | LUCID CAPITAL MARKETS | Dev Prasad | Buy | Initiates | $13.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Nov 4, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $16.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $20.00 |
| Jul 10, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $20.00 |
| Jul 9, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $20.00 |
| Jun 27, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $20.00 |
| May 14, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $20.00 |
| Apr 1, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $14.00 |
| Apr 1, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $20.00 |
| Mar 13, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $20.00 |
| Feb 16, 2024 | JonesTrading | Catherine Novack | Buy | Initiates | $22.00 |
| Feb 13, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $20.00 |
| Jan 29, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Initiates | $20.00 |
| Nov 13, 2023 | Oppenheimer | Leland Gershell | Outperform | Reiterates | $14.00 |
| Jul 7, 2023 | EF Hutton | Buy | Reiterates | $N/A | |
| Jun 20, 2023 | EF Hutton | Buy | Initiates | $N/A |
Calcimedica Inc. (CALC) Competitors
The following stocks are similar to Calcimedica based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CALC
CalciMedica
mkt cap
84.30M
Calcimedica Inc. (CALC) Financial Data
Calcimedica Inc. has a market capitalization of $78.82M with a P/E ratio of 0.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -526.4%.
Valuation Metrics
Market Cap
$78.82M
Enterprise Value
$74.79M
P/E Ratio
0.3x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+17.9%
Current Ratio
4.0x
Debt/Equity
-33.2x
ROE
-526.4%
ROA
-100.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Calcimedica Inc. (CALC) Business Model
About Calcimedica Inc.
What They Do
Develops therapies targeting calcium-release-activated channels.
Business Model
Calcimedica Inc. operates as a biopharmaceutical company focused on R&D of innovative treatments for inflammatory diseases. The company generates revenue through the development and commercialization of targeted CRAC channel inhibitors that modulate the immune system, aiming to address significant unmet medical needs in conditions like acute pancreatitis and acute lung injuries.
Additional Information
Calcimedica is positioned at the intersection of biotechnology and healthcare, contributing to advancements in the management of severe inflammatory conditions. Its work highlights the importance of targeted molecular therapies in the biotech sector and the pharmaceutical landscape.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
15
CEO
Dr. A. Rachel Leheny Ph.D.
Country
United States
IPO Year
2023
Website
calcimedica.comCalcimedica Inc. (CALC) Latest News & Analysis
Latest News
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
2 months ago
Quick Summary
CalciMedica's Phase 2 KOURAGE trial for Auxora™ in AKI is ongoing, with data expected in 1H 2026. Positive FDA discussions for a pivotal trial in AP and cash to fund operations into 2H 2026.
Why It Matters
CalciMedica's ongoing trials and positive FDA discussions signal potential advancements in treatments for serious conditions, which could enhance market confidence and drive stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CalciMedica's CM5480 shows promise as a first-in-class therapy for pulmonary arterial hypertension (PAH) and is also being evaluated for acute kidney injury in a Phase 2 trial.
Why It Matters
Positive preclinical data for CM5480 may indicate a breakthrough treatment for PAH, potentially enhancing CalciMedica's market position and driving investor interest in its future trials and market prospects.
Source: PRNewsWire
Market Sentiment:
Neutral
CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
2 months ago
Quick Summary
CalciMedica's Auxora shows promise in treating severe acute kidney injury (AKI) by reducing inflammation and improving kidney function in a rat model. It is currently in Phase 2 trials.
Why It Matters
Positive results from CalciMedica's Auxora in treating acute kidney injury (AKI) could enhance investor confidence, potentially boosting stock prices and market interest in the company's ongoing trials.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CalciMedica partners with Telperian to utilize AI tools for analyzing Phase 2 datasets, aiming to refine patient targets and efficacy endpoints for upcoming pivotal trials of Auxora™.
Why It Matters
CalciMedica's AI collaboration enhances data analysis for clinical trials, improving precision in targeting patient populations and efficacy, potentially boosting trial success and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
4 months ago
Quick Summary
CalciMedica Inc. (Nasdaq: CALC) announced the appointment of Rachel Leheny, Ph.D., as part of its focus on developing CRAC channel inhibition therapies for inflammatory diseases.
Why It Matters
CalciMedica's announcement of leadership, especially in a clinical-stage setting, may signal advancements in its drug development pipeline, impacting investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
5 months ago
Quick Summary
CalciMedica's Phase 2 KOURAGE trial for Auxora™ in AKI is ongoing, with data expected in 2026. Initial FDA discussions for Auxora in AP are positive, with pivotal trial planned for late 2025. Cash supports operations until mid-2026.
Why It Matters
Updates on CalciMedica's clinical trials and cash position signal potential for future revenue from product approvals, impacting stock valuation and investor confidence in the company’s growth prospects.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CALC Stock
What is Calcimedica Inc.'s (CALC) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Calcimedica Inc. (CALC) has a median price target of $15.50. The highest price target is $20.00 and the lowest is $14.00.
Is CALC stock a good investment in 2026?
According to current analyst ratings, CALC has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.47. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CALC stock?
Wall Street analysts predict CALC stock could reach $15.50 in the next 12 months. This represents a 183.4% increase from the current price of $5.47. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Calcimedica Inc.'s business model?
Calcimedica Inc. operates as a biopharmaceutical company focused on R&D of innovative treatments for inflammatory diseases. The company generates revenue through the development and commercialization of targeted CRAC channel inhibitors that modulate the immune system, aiming to address significant unmet medical needs in conditions like acute pancreatitis and acute lung injuries.
What is the highest forecasted price for CALC Calcimedica Inc.?
The highest price target for CALC is $20.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 265.6% increase from the current price of $5.47.
What is the lowest forecasted price for CALC Calcimedica Inc.?
The lowest price target for CALC is $14.00 from Leland Gershell at Oppenheimer, which represents a 155.9% increase from the current price of $5.47.
What is the overall CALC consensus from analysts for Calcimedica Inc.?
The overall analyst consensus for CALC is bullish. Out of 6 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $15.50.
How accurate are CALC stock price projections?
Stock price projections, including those for Calcimedica Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 7:20 AM UTC